Navigation Links
Sosei Agrees Terms With ASKA for Commercialisation of SOH-075 (NorLevo(R))
Date:10/21/2008

TOKYO, October 22 /PRNewswire-FirstCall/ -- Sosei Group Corporation ("Sosei"; TSE Mothers Index: 4565), the biopharmaceutical company, today announced that Sosei Co., Ltd., its wholly owned Japanese subsidiary, has entered into a binding letter of agreement with ASKA Pharmaceuticals Co., Ltd. ("ASKA", TSE First Section Index: 4514) for the commercialization of the emergency contraceptive pill SOH-075 (NorLevo(R)).

NorLevo(R) is an oral emergency contraceptive "morning after pill" which is used to prevent unwanted pregnancy after unprotected intercourse. NorLevo(R) contains only levonorgestrel as an active ingredient. The dosing is started within 72 hours after unprotected sexual intercourse. NorLevo(R) was first launched in Europe in 1999 and is currently approved in some 60 countries; the product being both safe and effective as an oral emergency contraceptive for post-coital use. Sosei acquired the exclusive distribution rights to the product in Japan from HRA Pharma. The Phase III study was completed in October 2008, and filing of the NDA in Japan is planned for the first half of 2009.

Under the terms of the agreement Sosei will be responsible for Development and registration and ASKA for sales and marketing. A joint committee will be established to oversee all the commercialisation activities. As part of the deal structure, Sosei will receive upfront and milestone payments as well as a significant portion of net sales. ASKA will also acquire shares of Sosei.

With its current product line-up, which includes oral contraceptive pills and infertility drugs, ASKA has taken a significant share of the Japanese obstetric and gynaecologic market. Now, as the anticipated marketing of a menopause disorder patch at the beginning of 2009 approaches, ASKA is focusing on further enhancement of its position in these therapeutic areas.

The agreement underscores Sosei's wish to make a contribution to women's health in Japan.

Notes to Edit
'/>"/>

SOURCE Sosei Group Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sosei Announces Outcome of Strategy Review
2. Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome
3. Deloitte Agrees to Acquire Recombinant Capital, A Leading Life Sciences Subscription Database and Advisory Services Firm
4. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
5. FDA Agrees to Review Cimzia(R) File for the Treatment of Rheumatoid Arthritis
6. Inverness Medical Innovations Agrees to Acquire ParadigmHealth
7. Inverness Medical Innovations Agrees to Acquire Panbio Ltd.
8. 2007 Another Record Year in Terms of Sales and Earnings for Gerresheimer
9. Prometic reaches understanding for commercialisation of several biopharmaceutical products and strategic investment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)...  Galmed Pharmaceuticals Ltd. (Nasdaq: GLMD ) ... and commercialization of a once-daily, oral therapy for the ... financial results for the period ended June 30, 2014. ... Reported cash and cash equivalents totaling $37.4 million on ... 2013.  , Reported a net loss of $3.9 ...
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... Calif. , July 24, 2014  Asterias ... in the emerging field of regenerative medicine, announced ... of a presentation to investors on Tuesday, July ... PDT.  The presentation will include an overview of ... access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at ...
(Date:7/24/2014)... Yet, scientists are making progress in devising suitable ... approach relies on quantum dotsa kind of artificial ... A new study demonstrates that changing the coupling ... electrical impulses can help better control them. This ... as quantum information units, which would produce faster ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... Cycle built a significant presence in the bicycle industry ... on the market. But the Madison, Wis.-based company has ... of radio frequency identification (RFID) technology into its systems. ... Schwinn, Murray and Roadmaster along with newer names such ...
... women entrepreneurs? , ,The market is good for their ... and the revenue from them has increased faster than the ... less likely to fail, too, experts say. , ,Finding money ... , ,The problem is not limited to Wisconsin, but is ...
... Neurognostics, Inc ., a Wisconsin company specializing ... announced today that the Food and Drug Administration (FDA) ... its trademarked MindState fDAD. MindState fDAD had previously ... acquisition device. The Special 510(k) allows Neurognostics to enhance ...
Cached Biology Technology:Pacific Cycle rides full speed into RFID 2Pacific Cycle rides full speed into RFID 3Women and Capital: Two words that dont always marry 2Women and Capital: Two words that dont always marry 3Women and Capital: Two words that dont always marry 4
(Date:7/24/2014)... sticky research out of York University shows a surprisingly ... toxic grass fungus: moose saliva (yes moose saliva). ... "Ungulate saliva inhibits a grassendophyte mutualism" shows that moose ... (which hosts a fungus called epichlo festucae that produces ... less toxicity. , "Plants have evolved defense mechanisms to ...
(Date:7/24/2014)... researchers has developed a new nanoscale agent for imaging ... assessing the function and properties of the GI tract ... treatment of gut diseases. , Illnesses such ... inflammatory bowel disease all occur in the intestine and ... diseases such as diabetes and Parkinson,s. , Until ...
(Date:7/24/2014)... at The University of Texas Health Science Center at ... to help Harris County residents whose vision problems cannot ... with corrective lenses, many people with low vision can ... of low vision devices, such as telescopes, magnifiers and ... Iyer is using the three-year, $164,645 SightFirst grant from ...
Breaking Biology News(10 mins):Moose drool inhibits growth of toxic fungus: York U research 2New imaging agent provides better picture of the gut 2UTHealth Dr. Bhavani Iyer awarded low vision grant 2
... who are exposed to manganese from welding fumes, risk developing ... exposure has ceased. This is the finding of a study ... It is estimated that 35,000 people in Sweden work ... one of several workplace activities. Previous research has shown that ...
... new strategies are needed to find and treat individuals ... disease. The prevalence of asymptomatic or minimally symptomatic malaria ... with malaria and these asymptomatic individuals can serve as ... disease transmission has declined. In a new ...
... The National Foundation for Cancer Research announced today that ... awarded the 7th annual Szent-Gyrgyi Prize for Progress in ... the successful development of a new therapeutic approach to ... traditional Chinese medicine with Western medicine, Drs. Wang and ...
Cached Biology News:Increased clumsiness in former welders 2'Test and Treat' model offers new strategy for eliminating malaria 2Chinese scientists Zhen-Yi Wang and Zhu Chen awarded 7th annual Szent-Gyorgyi Prize 2
This is a PYREX replacement Allihn condenser with a 34/45 inner joint on the bottom for the No. CLS3840-S 125mL extractor system. The tubulation O.D. on the condenser is 10mm....
... unique human proteins on a 1x3 ... a cross section of all cellular ... high-quality results. Additional control proteins and ... validity and reproducibility., ,UNIchip protein microarrays ...
... unique human proteins on a 1x3 ... all intracellular proteins (IP) according to ... quadruplicate for high-quality results. Additional control ... guarantee high validity and reproducibility., UNIchip ...
...
Biology Products: